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  Surgical resection of colorectal cancer metastasis to 
the liver results in a 5-year survival rate of around 40% . 
Liver metastasis from other cancers such as neuroen-
docrine carcinoma and genitourinary tumors are  a lso
treated effectively with combined liver resection. How-
ever, hepatic metastasectomy for liver tumor from gastric 
cancer hasn't been considered as a standard treatment, 
and the benefit for this treatment has not been estab-
lished. W e report here on two cases of gastrectomy and 
combined liver resection for synchronous liver metas-
tasis without any evidence of other metastatic lesions, 
and these two patients have survived for more than 7  
years without evidence of disease recurrence. In conclu-
sion, for patients with hepatic metastasis from gastric 
cancer, combined surgical resection of the liver 
metastasis should be considered as a treatment option 
when metastasis to other sites can be excluded. (Cancer 
Res Treat. 2006;38:184-188)
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INTRODUCTION
  The liver is a common site of hematogenous metastasis from 
gastrointestinal malignancies because it is the first major organ 
that the venous blood reaches after it drains from the primary 
site. The benefit of performing hepatic resection for liver metas-
tases has been established in selected patients who are suffering 
from some malignancies such as colorectal, neuroendocrine and 
genitourinary cancers, and a consensus has been reached in fa-
vor of hepatic metastasectomy.
  On the other hand, the prognosis of hepatic metastasis from 
gastric cancer, when this is recognized, is poor. The tumor is 
generally scattered throughout both lobes of the liver and this 
is frequently accompanied with peritoneal dissemination. Thus, 
in contrast to the hepatic lesions arising from colorectal metas-
tases, curative resection of metastases from gastric cancer is not 
obtainable in most cases (1). Nonetheless, complete surgical 
resection of the primary tumor and the liver metastases appears 
to be the only option for possibly curing the disease, although 
the benefits of surgical metastasectomy of gastric cancer are 
poorly defined.
  We report here on two long-term survivors, both who sur-
vived more than 7 years and who underwent curative gastrec-
tomy with combined liver resections for synchronous hepatic 
metastases from gastric cancer.
CASE REPORT
    1) Case 1
  A 62-year-old male patient initially presented at our hospital 
with a complaint of dyspepsia for the previous 4 months. He 
had no history of another chronic illness and no family history 
of gastric cancer. On admission, the physical examination was 
unremarkable and his functional performance status was Eastern 
Cooperative Oncology Group (ECOG) 1. On endoscopic biop-
sy, he was diagnosed as suffering with gastric adenocarcinoma 
of Borrmann's type III that involved the antrum. Abdomino- 
pelvic computed tomography (CT) demonstrated several enlarg-
ed perigastric lymph nodes without other obvious metastatic le-
sions in the liver, except for the dilated intrahepatic and com-
mon hepatic ducts. Abdominal ultrasound showed a small hy-
poechoic lesion in segment 2 of the liver. In June 1997, radical 
subtotal gastrectomy (D2 resection) and wedge resection of the 
liver were performed after intraoperative verification of a 1×1 
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Fig. 1. The macroscopic and microscopic finding of the first case. (A) and (B), gross findings of the gastrectomized stomach showing 
an ulcerofungating mass (arrow) that measured 3.5×4.0 cm on the posterior wall of the antrum. (C) Poorly differentiated adenocarcinoma 
with lymphocytic infiltrates in the surrounding stroma of the stomach (H&E, ×40). (D) Microscopic findings of the metastatic 
adenonocarcinoma of the liver (H&E, ×40).
cm sized palpable nodule that was highly suspicious for metas-
tasis. Macroscopically, the stomach revealed a 3.5×4.0 cm 
sized ulcerofungating mass located at the posterior wall of the 
antrum, and the diameter of the resected liver mass was 0.8×
0.6 cm. Microscopic examination revealed that the gastric mass 
was a poorly differentiated adenocarcinoma that expanded to 
the proper muscle along with metastases in 28 of the 44 lymph 
nodes. As shown in Fig. 1, the resected liver mass was a poorly 
differentiated adenocarcinoma that showed the same pathology 
as that of stomach mass, which was compatible with the liver 
metastasis. The procured tumor-free resection margin of the liv-
er was only 0.2 mm. The patient's final stage was pT2N3M1, 
and he underwent postoperative combination chemotherapy 
with 6 cycles of a 5-fluorouracil, etoposide, and cisplatin (FEP) 
regimen. He has survived for more than 9 years (109+months) 
without any evidence of recurrence, and the last follow was 
July 2006. The case is summarized in Table 1. 
    2) Case 2
  The second case is a 43-year-old male patient who visited 
our hospital with complaints of hunger pains for the previous 
5 months. His physical examination and laboratory findings were 
unremarkable, and his performance status was ECOG 1. He was 
diagnosed as having stomach cancer of Borrmann's type II in-
volving the upper body, and adenocarcinoma was confirmed by 
endoscopic biopsy. Abdomino-pelvic CT scan showed a single 
low-attenuated mass in segment 8 of the liver without evidence 
of other metastasis. Considering the patient's favorable general 
condition and single hepatic metastasis, radical total gastrecto-
my (D2 resection) with combined liver resection was perform-
ed. The patient also underwent coincidental splenectomy due 
to intraoperative detection of an enlarged splenic hilar lymph 
node. On operation, a single 4×4 cm sized mass was discover-
ed in segment 8 of the liver without other evidence of intra- 
abdominal metastasis. Macroscopically, the gastric specimen was 
an ulcerative lesion that measured 7×9 cm, and it was located 
at the posterior wall of the cardia and upper body. On multiple 
cut sections of the liver mass, the parenchyma revealed a 4×4 
cm sized well-circumscribed, friable gray tan nodular area that 
grossly abutted to one of the surgical margins. Histopathologic
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Fig. 2. The macroscopic and microscopic findings of the second case. (A) Removed stomach and spleen with a 7×9 cm sized ulcerative 
lesion on the posterior wall of the cardia and upper body. (B) The resected segment 8 of the liver showing a well-circumscribed 4×4 
cm sized, friable gray tan nodular area on the cut section. It grossly abuts to one of the surgical margins. (C) Moderately differentiated 
adenocarcinoma of stomach (H&E, ×40). (D) Metastatic adenocarcinoma of the liver (H&E, ×40).
Table 1. Clinico-pathological characteristics of the long-term survivors who underwent gastrectomy and combined hepatic metastasectomy 
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Case 1 2
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
Gender/age Male/62 Male/43
Size of liver metastasis (long diameter, cm) 0.8 4.0
Depth of invasion of the stomach wall Proper muscle Perigastric fat
Lymph nodes metastasis (positive/dissected) 28/44 13/38
Pathologic type Poorly differentiated adenocarcinoma Moderately adenocarcinoma
Type of metastasectomy Wedge resection Segmentectomy
Resection margin of liver resection Negative (0.2 mm) Negative (0.2 mm)
Timing of diagnosis and resection Synchronous Synchronous
Chemotherapy FEP* (6 cycles) FAM† (12 cycles)
Outcome after surgery 109+months without recurrence 94+months without recurrence
󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏
*5-Fluorouracil-Etoposide-Cisplatin, †5-Fluorouracil-Adriamycin-Mitomycin-C.
examination showed moderately differentiated adenocarcinoma 
extending to the perigastric fat tissue and lymphovascular per-
meation with metastasis to 13 of the 38 lymph nodes. The re-
sected liver showed a moderately differentiated adenocarcinoma 
that exhibited the same pathology as that of the stomach mass, 
which was compatible with the liver metastasis from the gastric 
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cancer (Fig. 2). The final stage was pT3N2M1, and the patient 
received 12 cycles of postoperative combination chemotherapy 
of 5-fluorouracil, doxorubicin and mitomycin-C (FAM). The pa-
tient has survived for 8 years (94+months) without evidence 
of recurrence with the last follow-up in July 2006. The case 
is summarized in Table 1.
DISCUSSION
  Gastric cancer with liver metastasis remains a non-curative 
disease; the median survival duration rarely exceeds 7 months 
and even intensive systemic chemotherapy does not achieve a 
satisfactory survival benefit. The liver is the major site of me-
tastasis from gastric cancer, and the incidence of liver metas-
tasis has been reported to be 5～10% (2,3). Therefore, liver me-
tastasis is a significant prognostic factor for the survival of gas-
tric cancer patients. 
  The benefit of metastasectomy in gastric cancer has not yet 
been well defined, and it is not considered as a standard treat-
ment. This is because hepatic metastases from gastric cancer are 
usually multiple lesions scattered to both lobes of the liver, and 
it is also accompanied with widespread peritoneal dissemina-
tion. However, if complete surgical resection of the primary tu-
mor and liver metastases is possible, it could be the only treat-
ment modality that offers the potential for cure. Nevertheless, 
further information on the indications and patient selection is 
still lacking, and the debate on hepatic metastasectomy in gas-
tric cancer is ongoing.
  The rationale of combined hepatic resection is well establish-
ed for some cancers such as colorectal cancer. The reported 5- 
year survival rate after curative resection for liver metastases of 
colorectal cancer ranges from 30% to 51% (4～8). From these 
data, a consensus has been made in favor of hepatic metastasec-
tomy in the case of unilobar involvement together with three 
or fewer metastatic nodules (1,9). Moreover, some authors have 
also expanded its indications to include all technically resecta-
ble metastases irrespective of the numbers (6～8).
  Some reports favor performing metastasectomy for advanced 
gastric cancer whenever possible. However, little is known about 
factors influencing the prognosis after resection of hepatic me-
tastasis from gastric cancer because of the small number of 
cases. A consensus has not yet been reached, and there is a de-
finite need for further study. The first point to consider for the 
indications of performing combined hepatic resection of metas-
tatic gastric cancer is the attainable resection margin. Miyazaki 
et al. reported a significant survival difference according to the 
tumor-free hepatic resection margin. He demonstrated signifi-
cantly longer survival in the group that procured a resection 
margin of more than 10 mm (10). In our cases, we could gua-
rantee R0 resection, but the tumor free hepatic resection margin 
was only 0.2 mm in both the two cases. An inadequate surgical 
margin could influence the subsequent treatment strategy. Our 
patients did not received radiotherapy, but they received postop-
erative systemic chemotherapy for the purpose of eradicating mi-
crometastasis. The role of the radiotherapy and/or chemotherapy 
after metastasectomy remains to be established, and the influen-
ce of the resection margin on the prognosis in such patients need 
further studies. 
  The second point is the number of hepatic nodules. Okano 
et al. reported survival rates of 56% for single metastasis, but 
they didn't report any survival rates for multiple metastases af-
ter hepatectomy (11). Another report also suggested the impor-
tance of the number of liver metastases as a prognostic factor 
(10). It is no wonder that the number of hepatic nodules is re-
lated to the postoperative hepatic reservoir and the feasibility 
of resection. Although our two patients had only a single he-
patic nodule, respectively, it is hard to draw any conclusions 
on the relationship between the number of metastases and its 
influence on the survival because there were only two patients 
in our study. However, it can be suggest that patient with a sin-
gle metastasis could be a candidate for combined metastasectomy. 
  The third point is the timing of the diagnosis of liver metas-
tasis and its resection. Some authors showed more favorable out-
comes for patients with metachronous metastasis as compared 
to patients with synchronous metastasis (11～13). On the 
other hand, other authors reported conflicting results that favored 
long-term survival for synchronous metastasis (1,14,15). In our 
cases, both of the patients had synchronous metastasis and they 
have survived for more than 7 years, suggesting that even in 
case of synchronous metastasis from gastric cancer, hepatic 
resection should be considered if curative resection is possible. 
  The last point is the size of metastatic lesion. It is logical to 
assume that a patient with a larger metastatic tumor will have 
a poor prognosis. However, the relationship between the size of 
metastatic tumor and patient outcome is as of now unclear. 
  In Korea, Roh et al studied about 11 patients who underwent 
hepatic resection and gastrectomy, and they found that 2 pa-
tients (18%) obtained long-term survival (15). The first survivor 
has submucosa-limited carcinoma with synchronous liver me-
tastasis, and this patient survived for 102 months after comb-
ined resection. The other survivor had metachronous hepatic me-
tastasis that was detected 37 months after gastrectomy. Segment-
ectomy of liver was performed and the patient survived for over 
9 months after hepatic resection (15). These findings suggest 
that there could exist a certain subgroup of patients that can be-
nefit from hepatic metastasectomy, although it is not considered 
as a standard treatment for gastric cancer. More data and clin-
ical experiences are required to clarify the role of hepatic 
metastasectomy in gastric cancer, and also to determine its in-
dications. 
  Thanks to the recent development of imaging tools such as 
positron emission tomography (PET), it is possible to detect me-
tastasis more accurately at a relatively early stage. In conclu-
sion, surgical hepatectomy should be considered as a treatment 
option when metastasis to other site can be excluded.
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